SCHEMBL30730484

SCHEMBL30730484

Cc1nonc1CC(=O)N1CCC(c2cnc(-c3ccc(F)cc3)nc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.49
TSHR P16473 2/20 0.49
MAPK1 P28482 2/20 0.49
ALOX15 P16050 1/20 0.49
PKM P14618 1/20 0.45
ALDH1A1 P00352 3/20 0.43
KMT2A Q03164 2/20 0.43
GFER P55789 1/20 0.41
POLB P06746 1/20 0.41
GRIN2B Q13224 3/20 0.40
MEN1 O00255 1/20 0.39
RAB9A P51151 1/20 0.39
EGLN1 Q9GZT9 2/20 0.39
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39
TUBB3 Q13509 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730486 0.86 KMT2A (0.45) LMNATSHRMAPK1ALOX15PKM
SCHEMBL30730662 0.84 LMNA (0.71) LMNATSHRMAPK1ALOX15ALDH1A1
SCHEMBL30730513 0.83 LMNA (0.48) LMNATSHRMAPK1ALOX15PKM
SCHEMBL30730612 0.81 LMNA (0.45) LMNATSHRMAPK1ALOX15PKM
SCHEMBL30730691 0.81 LMNA (0.46) LMNATSHRMAPK1ALOX15PKM
SCHEMBL30730690 0.81 LMNA (0.46) LMNATSHRMAPK1ALOX15PKM
SCHEMBL30730482 0.80 LMNA (0.48) LMNATSHRMAPK1ALOX15PKM
SCHEMBL30730510 0.80 TNKS (0.50) LMNATSHRMAPK1ALOX15PKM
SCHEMBL30730585 0.79 LMNA (0.47) LMNATSHRMAPK1ALOX15PKM
SCHEMBL30730501 0.79 LMNA (0.49) LMNATSHRMAPK1ALOX15PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 LMNA 1838/4885TSHR 620/4885MAPK1 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.